Impact of age on the toxicity of immune checkpoint inhibition

Indications for immune checkpoint inhibitor therapy are increasing. As the population ages, many patients receiving such drugs will be older adults. Such patients are under-represented in clinical trials, and therefore the safety of immune checkpoint inhibitors in this population has not been adequa...

Descripción completa

Detalles Bibliográficos
Autores principales: Samani, Amit, Zhang, Shuai, Spiers, Laura, Suwaidan, Ali Abdulnabi, Merrick, Sophie, Tippu, Zayd, Payne, Miranda, Faust, Guy, Papa, Sophie, Fields, Paul, Van Hemelrijck, Mieke, Josephs, Debra H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545628/
https://www.ncbi.nlm.nih.gov/pubmed/33033183
http://dx.doi.org/10.1136/jitc-2020-000871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545628/
https://www.ncbi.nlm.nih.gov/pubmed/33033183
http://dx.doi.org/10.1136/jitc-2020-000871

Ejemplares similares